Drugs / allo-APZ2-OTS
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05838092 | Oct 2023 → Aug 2025 overdue | epidermolysis bullosa | RHEACELL GmbH & Co. KG | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05464381 | Jun 2023 → Aug 2025 overdue | epidermolysis bullosa | RHEACELL GmbH & Co. KG | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allo-APZ2-OTS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05838092 ↗ |
| Modality | Cell therapy | “Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)” NCT05838092 ↗ |
| Route | Intravenous | “allo-APZ2-OTS administered intravenously” NCT05464381 ↗ |